Brief: Galectin Therapeutics - NAVIGATE Trial In NASH Cirrhosis Now Underway In All Countries Originally Selected Full Enrollment Expected By Mid-2022
13/12/2021 13:20
Dec 13 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS - NAVIGATE TRIAL IN NASH CIRRHOSIS
NOW
UNDERWAY IN ALL COUNTRIES ORIGINALLY SELECTED; FULL ENROLLMENT
EXPECTED BY MID-2022
Source text for Eikon: ID:nGNX5vkxP0
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study